Share

October 2016; 3 (5) ArticleOpen Access

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS

Joakim Bergman, Ann Dring, Henrik Zetterberg, Kaj Blennow, Niklas Norgren, Jonathan Gilthorpe, Tommy Bergenheim, Anders Svenningsson
First published August 2, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000271
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2093

Share

Article Information

vol. 3 no. 5 e271
DOI: 
https://doi.org/10.1212/NXI.0000000000000271
PubMed: 
27536708
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received March 3, 2016
  • Accepted in final form June 29, 2016
  • First Published August 2, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Joakim Bergman, MD,
    2. Ann Dring, PhD,
    3. Henrik Zetterberg, MD,
    4. Kaj Blennow, MD,
    5. Niklas Norgren, PhD,
    6. Jonathan Gilthorpe, PhD,
    7. Tommy Bergenheim, MD and
    8. Anders Svenningsson, MD
  1. Joakim Bergman, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Ann Dring, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Henrik Zetterberg, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) The Swedish Research Council (K2010-63P-21562-01-4, K2011-61X-20401-05-6); (2) Swedish State Support for Clinical Research (ALFGBG-144341); (3) VINNOVA; (4) the Knut and Alice Wallenberg Foundation; (5) the European Research Council; and (6) Frimurarestiftelsen

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Kaj Blennow, MD,
    5. Scientific Advisory Boards:

    1. Dr Blennow has served at advisory boards or as a consultant for Eli Lilly, IBL International, and Roche Diagnostics.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Fujirebio Europe

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Niklas Norgren, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am employed by UmanDiagnostics AB (been working for UmanDiagnostics since 2006)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jonathan Gilthorpe, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Tommy Bergenheim, MD and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Member of editorial board J Neurooncology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swedish Cancer Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Anders Svenningsson, MD
    9. Scientific Advisory Boards:

    1. Served in advisory board for Sanofi-Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Travel and congress expenses paid for by BiogenIdec, Sanofi- Genzyme, Novartis and Baxter Medical 2. Speaker honoraria from BiogenIdec and Sanofi-Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Non-conditional grant received from BiogenIdec

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society, Progressive MS Alliance, research grant no PA0185

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Pharmacology and Clinical Neuroscience (J.B., A.D., J.G., T.B., A.S.), Umeå University; Institute of Neuroscience and Physiology (H.Z., K.B.), Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Molecular Neuroscience (H.Z.), UCL Institute of Neurology, Queen Square, London, UK; UmanDiagnostics AB (N.N.), Umeå; and Department of Clinical Sciences (A.S.), Danderyd Hospital, Karolinska Institutet, Danderyd Hospital AB, Stockholm, Sweden.
  1. Correspondence to Dr. Svenningsson: anders.svenningsson{at}ki.se
View Full Text

Article usage

Article usage: August 2016 to December 2022

AbstractFullPdfSource
Aug 201631421852Highwire
Aug 201605934pmc
Sep 20163282424Highwire
Sep 201607847pmc
Oct 20163242955Highwire
Oct 201605833pmc
Nov 20168722914Highwire
Nov 201604323pmc
Dec 2016481710Highwire
Dec 201603516pmc
Jan 2017581814Highwire
Jan 201702510pmc
Feb 201742717Highwire
Feb 201702410pmc
Mar 2017251218Highwire
Mar 201704229pmc
Apr 201726820Highwire
Apr 2017111820pmc
May 201734917Highwire
May 2017203739pmc
Jun 201718035Highwire
Jun 2017162830pmc
Jul 201711118Highwire
Jul 201741518pmc
Aug 201718637Highwire
Aug 2017163341pmc
Sep 201716336Highwire
Sep 2017183030pmc
Oct 201712140Highwire
Oct 201782533pmc
Nov 201714931Highwire
Nov 2017112625pmc
Dec 20173955Highwire
Jan 20183977Highwire
Feb 201842921Highwire
Mar 201861729Highwire
Apr 201821122Highwire
Apr 2018162228pmc
May 201811912Highwire
Jun 20180308Highwire
Jun 2018112833pmc
Jul 20181352Highwire
Aug 20181328Highwire
Aug 2018112831pmc
Sep 20181314Highwire
Oct 20184257Highwire
Nov 20184418Highwire
Dec 20182276Highwire
Jan 201912348Highwire
Feb 2019166626Highwire
Mar 201933910Highwire
Apr 20195309Highwire
May 201982911Highwire
Jun 201974310Highwire
Jul 201973416Highwire
Aug 201932814Highwire
Sep 20196368Highwire
Oct 2019103513Highwire
Nov 201952510Highwire
Dec 201943826Highwire
Jan 2020122615Highwire
Feb 202044416Highwire
Mar 202065019Highwire
Apr 202081326Highwire
May 202033512Highwire
Jun 202083129Highwire
Jul 202062610Highwire
Aug 202032410Highwire
Sep 2020512224Highwire
Oct 202025115Highwire
Nov 202022413Highwire
Dec 202093733Highwire
Jan 2021104222Highwire
Feb 202152914Highwire
Mar 202153923Highwire
Apr 202153626Highwire
May 2021102910Highwire
Jun 2021104316Highwire
Jul 2021125024Highwire
Aug 202176215Highwire
Sep 202152725Highwire
Oct 20211210127Highwire
Nov 202143225Highwire
Dec 202164218Highwire
Jan 202252316Highwire
Feb 202234521Highwire
Mar 202252421Highwire
Apr 202239921Highwire
May 202283824Highwire
Jun 202259419Highwire
Jul 2022612212Highwire
Aug 2022721112Highwire
Sep 2022814618Highwire
Oct 2022125225Highwire
Nov 2022128231Highwire
Dec 2022104318Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me